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Abstract Cardiac diseases are the leading cause of death and
reach epidemic proportions with aging. Advanced heart
disease results from an abrupt or progressive loss of
contractile cardiomyocytes. Following percutaneous coronary
intervention and revascularization regenerative medicine aims
at effectively repair damaged tissue and replacement of lost
cardiomyocytes. However, mixed results were obtained from
trials using bone marrow-derived stem cells. Benefits were
rather attributed to paracrine effects leading to inhibition or
reverse of negative remodeling processes than to regeneration
of viable cardiomyocytes. Thus the aim of regenerative
medicine, in particular stem cell research, to generate viable
cardiac muscle has so far not been achieved in humans,
reflecting our incomplete understanding of underlying bio-
logical mechanisms. Moreover, there is growing evidence that
substantial person-to-person differences in the outcome of
stem cell therapy exists. We here review our present
knowledge in evolving stem cell based cardiovascular
medicine and highlight personalized aspects of stem cell
interventions.
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Introduction
The use of human stem cells is becoming pivotal for the
development of new therapeutic strategies for many organ-
specific diseases, which are characterized by abrupt or
progressive loss of function and for which existing therapies
are not satisfactory. Although state-of-the-art interventional
and medical therapy for myocardial infarction (MI) and heart
failure where implemented, clinical outcome remains poor in
post-MI patients with reduced left ventricular (LV) function.
The 1-year mortality rate is 13%, and the incidence of the
combined endpoint of death, recurrent infarction, or hospital-
ization for heart failure is 26% [1]. The majority of treatments
currently in use are straightened towards the general
population. In contrast personalized medicine is based on
targeted therapeutic approaches that allow patient specific
care [2] in order to maximize the therapeutic potential while
minimizing the risk of adverse effects. Regenerative medi-
cine, cellular therapy in particular, warrants a personalized
approach because of the multitude of interactions between
donor and host that can decisively influence treatment
outcomes [3]. Therefore, the precise planning of stem cell
therapy must be coordinated ideally with the characteristics
of individual patient profiles to fully harness its therapeutic
potential [4].
Given the aging of the western world population and the
increase in the prevalence of cardiovascular risk factors
such as obesity and type 2 diabetes, cardiovascular diseases
will continue to be a significant health concern in the
ongoing century [5, 6]. These trends suggest an unmet need
for therapies to regenerate or repair damaged cardiac tissue.
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After first promising results from stem and progenitor cell
transplantation in small animal models of cardiac ischemic
injury clinical researchers launched the exploration of cell
transfer strategies in acute and chronic ischemic human
heart disease (Fig. 1). In the emerging field of stem cell
research and therapy heterogeneous populations of stem
and progenitor cells residing in bone marrow (BM), adipose
tissue, and skeletal muscle or circulating in the blood
showed potential to be capable of improving myocardial
function (Fig. 1). Based on experimental data demonstrat-
ing that infusion or injection of stem/progenitor cells
derived from various sources enhance blood flow, neovascula-
rization and improve heart function after myocardial infarction
[7], clinical trials were started about a decade ago to treat
patients with cardiac ischemia [8, 9]. The primary goal of all
studies using stem and progenitor cells was to improve
myocardial function and reduce remodeling by replacement
of the fibrotic scar tissue with viable cardiac myocytes
(Fig. 2). Initial trials of autologous (BM)-derived stem cells
(BMC) documented safety and feasibility both in patients
with acute myocardial infarction and in those with chronic
ischemia and reported a modest, beneficial effect on LV
function [10–13]. The relatively small number of patients, the
absence of a control group undergoing repeat coronary
infusions, and the relatively mild improvements in LV
function after the index infarction challenged distinct inter-
pretation of these results concerning identification of patient
populations with particular benefit of stem cell interventions.
Fig. 1 Human stem cells and stem cell sources for cell-based
functional repair after myocardial ischemia. Patient-specific autolo-
gous approach by reprogrammed induced pluripotent stem cells or
multi- or monopotent adult stem cells compared to an allogenic
approach using pluripotent embryonic stem cells is depicted. Stem
cells from different sources can be expanded in vitro and differentiated
into cardiovascular progenitor cells and mature cardiovascular cells
(e.g. cardiomyocytes, red: α-actinin; endothelial cells, yellow: flt-1;
smooth muscle cells, green: α-smooth muscle actin). Monopotent
skeletal myoblasts proliferate and form multinucleated myotubes
(myotube, green: titin). Following PCI for revascularization cells will
be applied to the side of injury. Protocols in active randomized clinical
trials are ongoing to address issues of optimal timing, dose and route
of cell delivery. Abbreviations: PCI percutaneous coronary interven-
tion, CSC cardiac stem cells; BMC bone marrow cell, EPC endothelial
progenitor cell, MSC mesenchymal stem cell, SkM skeletal myoblast
120 EPMA Journal (2011) 2:119–130
Clinical experience of double-blind randomized
placebo-controlled studies
Two subsequent double-blind randomized placebo-controlled
studies, Leuven-AMI and REPAIR-AMI (Reinfusion of
Enriched Progenitor Cells and Infarct Remodeling in Acute
Myocardial Infarction) investigated a similar AMI population
using comparable BMC isolation, preparation, and character-
ization protocols [14, 15]. Thereby addressing some of these
confounding variables associated with bone marrow aspira-
tion and a second catheterization [16, 17]. Within clinical
trials, the largest randomized, controlled clinical study of
BMC therapy, the REPAIR-AMI trial, observed improve-
ment in left ventricular ejection fraction (LVEF) of 2.5% in
patients after MI, while the Leuven-AMI trial found an
improved LVEF of 1.2%. In addition, patients receiving cell
transfer in the Leuven-AMI trial had a significantly greater
reduction in infarct size for a similar area at risk, as assessed
using repeated MRI, and a greater recovery of regional
systolic function. Importantly, these beneficial effects were
sustained at 1-year follow-up [18]. Although these potential
effects of BMC therapy on LV function are less than many
investigators were hoping for, it should be noted that several
of our established clinical therapies with an impact on
prognosis in patients with MI and a reduced LV function,
such as angiotesinconverting enzyme (ACE) inhibitor or
ß-blocker therapy, are associated with similar improvements
in LVEF and have been observed in patients after MI with a
less optimal background therapy as compared with present
studies [19].
Population with most benefit of autologous BM-derived
stem cell (BMC) therapy
Within the REPAIR-AMI trial cell transfer was not always
performed on the same day after the index percutaneous
coronary intervention but ranged from 3 to 7 days, whereas
patients in the Leuven-AMI trial received placebo or BMC
infusion at 24 h after the first intervention. Interestingly,
when data were stratified by time of cell transfer and by
severity of LV dysfunction at baseline, the benefit was
predominantly observed in patients receiving delayed cell
transfer enabling ex vivo expansion of cells and autologous
transplantation. Moreover, patients with a baseline LVEF
below the median value of 49% showed significantly
enhanced metabolic recovery receiving cell transfer. Although
the studies were not powered to primarily evaluate the effects
of MI size, there was a significant interaction between infarct
severity and subsequent benefit from cell transfer [20–22].
Functional repair
by stem cell transfer
Cardiac regeneration
•Generation of viable cardiomyocytes
•Survival in recipient
•Integration into surrounding tissue
•Demonstration of functionality
•No intramyocardial calcification or tumors
•No increase of arrhythmias
•Immunologically compatible
Cardioprotection (trophic effects)
•Reduction of cardiomyocyte apoptosis
•Reduction of oxidative stress
•Neovascularization
•Reduction of fibrosis and remodeling
Fig. 2 Stem cell triggered myocardial repair via cardioprotection and
cardiomyocytes regeneration. Functional benefits obtained from trials
using bone marrow-derived stem cells were rather attributed to
trophic-paracrine effects (cardiprotection) leading to inhibition or
reverse of negative remodeling processes than to regeneration of
viable cardiomyocytes (cardiac regeneration)
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The best results were observed in patients suffering from
large infarctions (anterior infarction and significant LV
dysfunction) with more depressed global ejection fractions.
Concerning the timing of cell transplantation after MI it has
been speculated that by giving the cells sooner after the
index infarction the high incidence of microvascular obstruc-
tion that is observed in the early phase of reperfusion may
limit homing, engraftment, and survival of infused cells.
The large number of patients enrolled in the REPAIR-AMI
trial allowed to test several predefined secondary endpoints in
order to generate hypotheses for the next generation of clinical
trials. Indeed, the beneficial effect on clinical endpoints was
also preferentially observed in those patients with a lower
baseline ejection fraction. Therefore, these analyses are
generating the hypothesis that selecting patients with severe
impairment of LVEF after MI maybe one way to increase the
benefit of this therapy. This focus is consistent with the unmet
clinical need in this expanding population of ischemic
cardiomyopathy and represents the prime target in next-
generation clinical trials.
The degree of improvement of myocardial contractility and
perfusion observed in these trials depend substantially on the
functional quality and number of progenitor and stem cells
that can be harvested from the individual patient [23–26]. This
in turn is dependent on age, comorbidities, medications and
other factors. Numerous experiments have shown that in
patients with diabetes there is a functional impairment of the
BM-derived endothelial progenitor cells (EPC) and a lower
number of circulating pluripotent cells in comparison to
patients without diabetes. In addition, patients with ischemic
cardiomyopathy have fewer EPC in the BM, while the
migratory capacity of these cells is significantly impaired
[27]. Other studies have demonstrated shortening of the
telomeres in progenitor cells isolated from the BM and
peripheral blood in patients with coronary heart disease [28,
29]. Therefore, if autologous cells are used for myocardial
repair their functional status, which is dependent on the
individual risk profile of the patients, might profoundly
affect the outcome. Because the functional impairment of
BM-derived cells harvested from patients with chronic heart
failure may limit the efficiency of such treatment, and since
genetic engineering is not always possible, another way to
overcome the obstacles would be to use allogeneic BM-cells
isolated from healthy subjects. This requires isolation and
expansion of immunologically compatible cells suitable for
replacement therapies in senescent adults.
Transplantation of allogenic derived stem cells
Comparisons between allogenic and autologous transplant
therapies have demonstrated the critical role of the immune
system in determining clinical outcomes. Autologous trans-
plantations employ a patients own tissue and thus present
no tissue incompatibility between the donor and the host
due to a lack of stimulation of the immune response.
However, in cases where there is a need for immediate
treatment with stem cells, it will not be practical to wait for
ex vivo expansion and re-transplantation of autologous
stem cells [30]. Moreover, because the functional impair-
ment of stem and progenitor-derived cells harvested from
patients with chronic heart failure may limit the efficiency
of autologous stem cell treatment. The use of allogeneic
stem cells isolated from healthy subjects might offer a
promising alternative approach.
Mesenchymal (bone marrow stromal) cells (MSC)
MSC are so far the best candidate for this approach,
because they are immunoprivileged and escape rejection by
the release of immunomodulatory factors and inhibition of
T-cell proliferation. MSC are precursors of non-hematopoietic
tissues (e.g., muscle, bone, tendons, ligaments, adipose
tissue, and fibroblasts) that are obtained relatively easily
from autologous BM. MSC make up a small proportion of
BM cells (0.001–0.01% of nucleated cells in the bone
marrow), but can be harvested from the BM and even more
efficiently from the adipose tissue (ca. 1 million MSC per
100 cc of fat tissue). Importantly, the cells can be expanded
in vitro and stored [31, 32]. This would allow an available
treatment of patients with acute MI and severe left
ventricular dysfunction, without the need to wait for the cell
processing and expansion. The potential of MSC to undergo
cardiomyocyte differentiation is still under dispute, but
several experimental and clinical trials have shown their
potential to improve LV function in ischemic cardiomyop-
athy. Because of their ability to undergo expansion, MSC
can also be bioengineered to overexpress factors that
increase their engraftment and differentiation [33]. Several
animal model studies have shown that treatment with MSC
significantly increases myocardial function and capillary
formation [34]. A randomized clinical trial implanting
MSC after MI has demonstrated significant improvement
in global and regional LV function, and clinical trials are
currently underway to investigate the application of
allogeneic and autologous MSC for acute MI and myocardial
ischemia, respectively [13].
Heterogeneity among BMC transplanted stem cells
Initial trials of autologous BMC transfer have either used
unfractionated or mononuclear cell fractions in patients
after MI. BMC clearly represent a heterogeneous popula-
tion of cells, so that it remains unclear which of the cells is
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particularly important for the potential effects on cardiac
repair. The pool of mononuclear cells isolated from the BM
by gradient centrifugation contains mostly committed cells,
a small number of monopotent progenitor cells, and even
fewer bona fide stem cells. Stem cells are defined as cells
that have the capacity to self renew, are multipotent/
pluriopotent, can be clonally expanded, and are divided
into embryonic stem cells and adult stem cells. In addition,
progenitor cells comprise cells which are already more
committed. Traditional views in stem cell biology held that
one particular tissue type arises from one particular stem
cell. As evidence of stem cell plasticity amounts, the
traditional views are fading away in favor of more complex
themes involving cross functions of stem cells. The effects
of environmental factors on stem and progenitor cell
behaviour are diverse and can include alteration of gene
expression within distinct populations. A single standard
method of culturing and expansion stem and progenitor
cells has not been established, and therefore comparison of
results of stem cell therapies may be difficult to interpret
based on different culture conditions. Furthermore the BM
microenvironment varies from person to person due to
multiple factors, including genomic differences and overall
health. Despite the influence of culture conditions, stem cells
show donor differences with regard to the gene expression,
although similar isolation protocols and variations can emerge
when cultures become confluent or are expanded by serial
passage while they approach senescence [35]. Therefore,
generalizations about the effect of stem cells are difficult
until variations among cell types, culture conditions, donors
and hosts are elucidated.
Mechanism of action
Despite rejection reactions of the immune system there are
several other reasons to suggest that the implementation of
personalized medicine with stem cells is required. Stem and
progenitor cells have particular niches in which they stay
until mobilization and to which they home in case of injury.
Several humoral factors govern and control these processes
[36]. Thus variations among microenvironments which
could be influenced by the patient’s background as well
as other underlying clinical disorders might be relevant for
the functions of stem cells in each different host [30]. The
composition of the microenvironment and the presence of
certain soluble factors are major determinants for proliferation,
differentiation and homing of applied stem or progenitor cells.
Knowledge on cytokines and growth factors present in injured
myocardium is limited. However, functions of transplanted
stem cell will depend on the discretion of paracrine factors
which may result in beneficial or undesirable outcomes.
Therefore identification of these factors, by secretome analyses
and bioinformatic approaches, will advance cell- and
protein-based therapies to promote healing and inhibit
pathological remodeling of the heart after ischemia. So
far, the results obtained in vitro do not ensure that
applied stem cells will provide the desired therapeutic
result in vivo. In vitro findings must be confirmed and
verified in vivo before translation to patients. It is critical
to conduct in vitro stem cell research with caution
because challenges can frequently re-appear when trans-
plantation is conducted in humans. Understanding of the
microenvironment factors of injured myocardium at the
relevant time must be ascertained in-depth in order to
optimize homing and differentiation processes. Moreover,
timeline, dose and route of application are critical for
stem cells to exert maximal beneficial effects, but current
evidence is not well supported regarding when particular
signals are present in injured tissue in order to have
optimal clinical benefits.
As basic science findings and knowledge on stem cell
biology continue to accumulate, questions are now emerging
on how to translate the existing stem cell research data
towards therapeutic applications that have predictable and
adequate clinical effectiveness. The entire process, from
patient profiling to delivery and maintenance of successful
stem cell therapy, will therefore require the understanding of
numerous factors that impact research and treatment
outcomes. The abundance of biological properties inherent
to stem and progenitor cells requires consideration of all
possible interactions they can have with the host.
Given the above argument, it appears that personalized
treatment regimens would require an understanding of
the molecular and cellular interactions with the prospec-
tive microenvironment. Through this information, thera-
peutic outcome of stem cell therapies would be better
predicted. Patient specific genomic profiling and molec-
ular understanding of stem cell biology are therefore the
major tasks for clinicians and scientists in order to reach
desirable results in future approaches, reminding us that
a complete understanding of basic science is fundamental
prior to and during implementation of these cell-based
interventions.
Nonetheless, the field is still evolving, and single clinical
failures should not interfere with the overarching favorable
evidence that has accumulated thus far.
Other stem cells regenerating damaged myocardium
and personalized treatments
The source of stem cells must be carefully chosen on
functional and physical criteria that lead to optimal out-
comes. The use of tissue-specific stem cells for repair has
been traditionally attempted. Despite unipolar progenitor
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cells multipotent stem cells have been shown to facilitate
the recovery of different tissue types. As mentioned above,
many types of stem cells have been applied to regenerate
damaged myocardium and demonstrated sufficient promise
to further explorate them in large-scale, controlled clinical
trials (Table 1). However, the lack of transdifferentiation of
BMC into cardiomyocytes and the absence of standardized
protocols has made it difficult to compare and contextualize
the results generated by the various trials. Most studies
published to date have enrolled fewer than 25 patients, and
the studies vary in terms of cell types and preparations
used, methods of delivery, patient populations, and trial
outcomes. However, the mixed results that have been
observed in these studies do not necessarily argue against
using stem cells for cardiac repair. Rather, preliminary
results illuminate the many gaps in understanding of the
mechanisms by which these cells regenerate myocardial
tissue and argue for improved characterization of cell
preparations and delivery methods to support clinical
applications.
Mesenchymal (bone marrow stromal) cells (MSC)
MSC are so far the best candidate for this approach,
because they are immunoprivileged and escape rejection
by the release of immunomodulatory factors and
inhibition of T-cell proliferation. MSC are precursors
of non-hematopoietic tissues (e.g., muscle, bone,
tendons, ligaments, adipose tissue, and fibroblasts) that
are obtained relatively easily from autologous BM. MSC
make up a small proportion of BM cells (0.001–0.01% of
nucleated cells in the bone marrow), but can be harvested
from the BM and even more efficiently from the adipose
tissue (ca. 1 million MSC per 100 cc of fat tissue).
Importantly, the cells can be expanded in vitro and stored
[31, 32]. This would allow an available treatment of
patients with acute MI and severe left ventricular
dysfunction, without the need to wait for the cell
processing and expansion. The potential of MSC to
undergo cardiomyocyte differentiation is still under
dispute, but several experimental and clinical trials have
Table 1 Pros and cons of different stem cell types suitable for personalized cardiovascular disease
Cell type Advantage Disadvantage
Embryonic stem cells (ESC)
Inner cell mass of blastocyst
• Autogous transplantation possible via
therapeutic cloning
• Social and ethical concerns
• Pluripotent and unlimited supply • Allogenic transplantation provokes immune
rejection
• Limited supply of human oocytes
• Risk of tumor formation
• Proarrhythmic risk due to immature phenotype of
derived cadiomyocytes
Induced pluripotent stem cell (iPS)
Skin/Fat Biopsy
• Patient-specific cells for autologous
transplantation possible
• Risk of tumor formation (viral vector
reprogramming)
• Pluripotent and unlimited supply • Proarrhythmic risk due to immature phenotypes of
derived cardiomyocytes
Adulte cardiac stem cells (CSC)
Heart
• Autologous transplantation without
immunosuppression
• Limited supply
• Cardiomyocyte progenitor with effectice
cardiomyocyte differentiation
• Difficult to isolate and propagate in vitro
• Integration with host cardiomyocytes
Endothelial progenitor cells (EPC)
Peripheral blood
• Autologous transplantation without
immunosuppression
• Limited ability to differentiate into cardiomyocytes
• Induction of angiogenesis • Limited supply and need for in vitro expansion
• Difficult to propagate in culutre
• Heterogenous population
Bone marrow stem cells
(BMC, EPC, MSC)
Bone marrow
• Autologous transplantation without
immunosuppression
• Limited ability to differentiate into cardiomyocytes
• Induction of angiogenesis • Limited supply and need for in vitro expansion
• MSC: Lower risk of rejection if allogenic
transplantated




• Autologous transplantation without the need for
immunosuppression
• Cannot transdifferentiate into cardiomyocytes
• Can be expanded in vitro with high yield,
resistant to ischemia
• Increased risk of arrhythmias
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shown their potential to improve LV function in ischemic
cardiomyopathy. Because of their ability to undergo expan-
sion, MSC can also be bioengineered to overexpress factors
that increase their engraftment and differentiation [33].
Several animal model studies have shown that treatment
with MSC significantly increases myocardial function and
capillary formation [34]. A randomized clinical trial implant-
ing MSC after MI has demonstrated significant improvement
in global and regional LV function, and clinical trials are
currently underway to investigate the application of alloge-
neic and autologous MSC for acute MI and myocardial
ischemia, respectively [13].
Embryonic stem cells (ESC)
Because ESC cells are pluripotent, they can potentially give
rise to a variety of cell types that are instrumental in
regenerating damaged myocardium, including cardiomyo-
cytes, endothelial cells, and smooth muscle cells (Fig. 1). To
this end, mouse and human ESC have been shown to
differentiate spontaneously to form endothelial and smooth
muscle cells in vitro and in vivo, and human ESC
differentiate into myocytes with the structural and functional
properties of cardiomyocytes [37, 38]. Moreover, ESC that
were transplanted into ischemically-injured myocardium in
rats differentiated into normal myocardial cells that remained
viable for up to 4 months, suggesting that these cells may be
candidates for regenerative therapy in humans [39].
Although the potential benefits of personalized stem
cell therapy are vast, as discussed above, implementation
of ESC in personalized therapy must first overcome other
significant obstacles. First, perhaps the most obvious
challenges to personalized therapy for ESC revolve
around immunogenicity, which can lead to rejection of
implanted cells. ESC are immunogenic as evident by
MHC expression, and MHC expression is increased
when ESC lose their pluripotency [40]. Hence, MHC
antigens must be matched as closely as possible to
minimize rejection [40]. In order to serve as stem cell
therapy autologous approaches with individual ESC
would have been to be generated for diverse patient
populations [41]. The generation of such a large number
of ESC lines would be impractical considering the ethical
and scientific limitations of harvesting these cells. Crea-
tion of a reliable source of stem cells may be more
difficult than previously thought [42].
Second, to ensure delivery of healthy stem cells, the cell
population must be purified prior to delivery into the host
because mutations in the genome or undifferentiated ESC
can lead to development of tumors, such as teratomas [40].
However, the purification process may induce unforeseen
genetic damage, and quality control must be performed
before delivery to the host. Transmission of infection by
ESC may also limit their use [41].
Aside from the biological challenges to the employment
of ESC in personalized medicine, numerous ethical issues
emerge. The source of ESC is the inner cell mass, which is
located in the blastocyst of a zygote (Fig. 1). Adult stem
cells, on the other hand, bypass these problems because
they can be obtained readily from the BM. Thus,
therapeutic avenues that arise from adult stem cells may
address some of the attendant socio-ethical concerns more
effectively compared to ESC investigations.
Skeletal myoblasts (SM)
While SM are committed progenitors of skeletal muscle
cells, their autologous origin, high proliferative potential,
commitment to a myogenic lineage, and resistance to
ischemia promoted their use as the first stem cell type to
be explored extensively for cardiac application. Studies in
rats and humans have demonstrated that these cells can
repopulate scar tissue and improve left ventricular function
following transplantation [43]. However, SM-derived myo-
cytes do not function in complete concert with native
myocardium. The expression of two key proteins involved
in electromechanical cell integration, N-cadherin and con-
nexin 43, are downregulated in differentiated myotubes, and
the engrafted cells develop a contractile activity phenotype
that appears to be unaffected by neighboring cardiomyocytes
[44, 45]. Although stem cells appear to be relatively safe in
the majority of recipients to date, an increased frequency of
non-sustained ventricular tachycardia, an arrhythmia, has
been reported in conjunction with the use of skeletal
myoblasts, possibly resulting from the lack of electrical
coupling between SM-derived myocytes and native tissue
[46, 47]. While this proarrhythmic effect occurs relatively
early after cell delivery and does not appear to be permanent,
its presence highlights the need for careful safety monitoring
when these cells are used. Additionally, animal models have
demonstrated that stem cells rapidly diffuse from the heart to
other organs (e.g., lungs, kidneys, liver, spleen) within a few
hours of transplantation, an effect observed regardless of
whether the cells are injected locally into the myocardium
[48]. This migration may or may not cause side-effects in
patients; however, it remains a concern related to the delivery
of all stem cells in humans.
Endothelial progenitor cells (EPC)
The endothelium is a layer of specialized cells that lines the
interior surface of all blood vessels including the heart. This
layer provides an interface between circulating blood and
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the vessel wall. EPC are BM-derived stem cells that are
recruited into the peripheral blood in response to tissue
ischemia [49]. EPC are precursor cells that express some
cell-surface markers characteristic of mature endothelium
and some of hematopoietic cells [50]. EPC home in on
ischemic areas, where they differentiate into new blood
vessels. The new vascularization induced by these cells
prevents cardiomyocyte apoptosis and LV remodeling,
thereby preserving ventricular function [51]. However, no
change has been observed in non-infarcted regions upon
EPC administration. The majority of clinical trials of
human cell therapy for various forms of ischemic vascular
disease have relied on autologous bone marrow-derived,
CD34+/KDR+ and CD133+ cells that have displayed
modest regenerative and reparative roles [52]. The level of
circulating CD34 + KDR + EPCs predicted the occurrence
of cardiovascular events and death from cardiovascular
causes in the analyzed study population [52]. Compared to
preclinical studies performed in rodent models clinical trials
have not been as efficacious as predicted. Conducted
studies have often lacked detailed characterization of
cellular function and lineage of origin resulting in the term
EPC encompassing different cell populations, including
cells of myeloid, lymphoid and endothelial origin. Not
surprisingly these putative EPC populations have demon-
strated a mixed ability to contribute to the regeneration or
formation of blood vessels [53]. Clinical trials are currently
underway to assess EPC therapy for growing new blood
vessels and regenerating myocardium.
Induced pluripotent stem cells (iPSC)
Recent progress with pluripotent stem cells and particularly
the use of iPS cells may enabeling researchers and clinicians
to develop patient specific therapies [54]. The major
therapeutic advantage of iPS cells over ES cells is related
to its source of origin. iPS cells can be derived from almost
any somatic tissue providing immunologic compatibility and
the lack of ethical controversies in human stem cell research.
These cell lines may therefore prove invaluable for thera-
peutic interventions and treatment of cardiac and vascular
diseases either through cell replacement or through secretion
of critical factors. These cells are genetically identical to the
donor cells [55]. One particularly appealing aspect of iPSCs
is that, in theory, they can be directed to differentiate into a
specified lineage that will support treatment or tissue
regeneration. Jet while iPSCs have great potential as sources
of adult mature cells, much remains to be learned about the
processes by which these cells differentiate. For example,
iPSCs created from human and murine fibroblasts can give
rise to functional cardiomyocytes that display hallmark
cardiac action potentials [56–59]. The proof-of-concept
studies showed that iPS can be efficiently differentiated into
cardiac lineage cells that demonstrate the expression of early
cardiac markers, followed by cardiac structural proteins,
eventually leading to the formation of spontaneously
contracting cardiomyocytes coupled by gap junctions. The
pattern of the transmembrane calcium currents and action
potential characteristics is similar to that of cardiomyocytes
derived from embryonic stem cells. However, the maturation
process and the electrophysiological properties of the
iPS-derived cardiomyocytes were impaired compared to that
seen with cardiomyocytes derived from ESC or fetal tissue
[57, 60]. Furthermore, variation exists in the expression of
genetic markers in the iPSC-derived cardiac cells as
compared to that seen in ESC-derived cardiomyocytes.
Therefore, iPSC-derived cardiomyocytes demonstrate normal
commitment but impaired maturation, and it is unclear
whether observed defects are due to technical or biological
barriers. Thus, before these cells can be used for therapy, it
will be critical to distinguish between iPSC-specific and
disease-specific phenotypes.
Unlike adult stem cells, iPS does show a potential to
generate tumors, probably due to the insertional mutagenesis,
so their use in humans cannot be envisioned in the near future.
A possible way to overcome the risk is to use viral-free vectors
and the proteins of reprogramming factors instead of DNA
encoding [61]. For putative regenerative medicine applica-
tions, patient safety is the foremost consideration. Standard-
ized methods must be developed to characterize iPSCs and
their derivatives. Furthermore, reprogramming has demon-
strated a proof-of-principle, jet the process is currently too
inefficient for routine clinical application. Thus, unraveling
the molecular mechanisms that govern reprogramming is a
critical first step toward standardizing protocols and person-
alized usage. Based on the exciting developments in this area
to date, induced pluripotent stem cells will likely support
future therapeutic interventions, either directly or as research
tools to establish novel models for degenerative disease, drug
screening or cell based therapies.
Despite replacement therapies designed to improve
cardiac and vascular function in compromised individual’s
iPS technology offers the unprecedented possibility of
using human cells to study human diseases for which there
are no animal models, such as Brugada syndrome and
hypertrophic cardiomyopathy [62]. iPS cells, when pro-
duced directly from patients with cardiovascular diseases of
unknown etiologies, will lead to the development of new
model systems that can be employed to investigate cardiac
and vascular developmental defects. This is an important
benefit given that many genetic diseases are of a sporadic
nature with no family history. More than ten human
disease-specific iPS cell lines have been established,
ranging from simple single gene deficiencies to complex
multifactorial diseases of unknown genetic origin [62].
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While much remains to be learned in the field of iPSC
research, the development of reprogramming techniques
represents a breakthrough that will ultimately open many
new avenues of research and therapy.
Resident cardiac stem cells (CSC)
Most of the cell transplantation-based therapeutic approaches
used so far are predicated on the concept that the adult
human myocardium does not have intrinsic regenerative
capacity because the working cardiomyocytes are termi-
nally differentiated cells with no regenerative capacity.
However, recent evidence suggests that the adult myocar-
dium contains a small population of endogenous stem
cells that most likely facilitate minor repair and turnover-
mediated cell replacement [63]. Several groups have
identified cardiac stem cells possessing growth factor-
receptor systems and reported different membrane markers
or transport proteins. These endogenous CSC are able to
regenerate the contractile myocytes and endothelial and
smooth muscle cells of the microvasculature, but their
numbers vary substantially between species, and it is
unclear whether they constitute phenotypic variations of a
unique cell type [64, 65].
The cells can be harvested in limited quantity from
human endomyocardial biopsy specimens and can be
injected into the site of infarction to promote cardiomyocyte
formation and improvements in systolic function [66, 67].
The problem is that these reservoirs of cells are usually
overridden in patients with AMI, advanced coronary artery
disease, and chronic heart failure. Despite this limited
capacity for regeneration of myocardium, the existence of
these repair mechanisms suggests that cardiac repair may be
achieved therapeutically in these clinical settings, given the
appropriate stimulation (in situ activation, multiplication
and differentiation of the eCSC) and/or adoptive transfer of
(stem) cells involved in these processes [68, 69]. Cardiac
repair via endogenous CSC represents a major target for
translational research in the years to come.
Non-biological challenges of stem cell therapies
Non-biological concerns include socio-political factors that
may hinder the implementation of personalized medicine in
cellular replacement therapies. The premium cost of
personalized services and therapies is a topic of heavy
debate in health policy [70]. A major point of discussion is
whether or not the absolute incremental increase in LVEF
of up to 2.99%, infarct remodeling, and recovery of
regional LV function translates into a meaningful clinical
benefit at longer-term follow-up and justify the additional
costs of cell-based interventions. There is currently a need
for enhanced clinical evidence of the benefit of personal-
ized medicine in order for marketed products to achieve
coverage [70]. Stem cell therapies suffer from relative
complexity and face significant cost constraints posed by
the need to make the treatment affordable to large numbers
of candidate patients. Moreover, the clinical requirement for
a readily available treatment that can be prepared and
administered in the majority of catheterization laboratories
during the early phase of the disease remains a major
challenge, especially of autologous cell therapies. To
circumvent some of these obstacles, a rapid and relatively
simple purification procedure should be proposed to isolate
the most suitable cell population. In addition to safety and
tracking, several logistical issues must also be addressed
before stem cells can be used routinely in the clinic. While
cell tracking methodologies allow researchers to determine
migration patterns, the stem cells must target their desired
destination and be retained there for a sufficient amount of
time to achieve benefit. To facilitate targeting and enable
clinical use, stem cells must be delivered easily and
efficiently to their sites of application. Finally, the ease by
which the cells can be obtained and the cost of cell
preparation will also influence their transition to the clinic.
Conclusion and future outlook
Although we have witnessed remarkable progress in this
exciting era of translational cell-based therapies for cardio-
vascular disorders, many outstanding questions remain. We
have to realize that treatment responses to stem cells depends
on interactions between the delivered stem cells and the cells
of the host, making cell-based therapy far more complex, and
host dependent than pharmacological therapy.
For the past decade, adult stem cells from the BM have been
the most attractive cells for clinicians to be used in cell therapy
because of their autologous nature and ease of isolation.
Although the patients who received BM-cell transplant had a
modest functional benefit, BM-cells did not reproducibly
generate new myocardium. The detected benefit was most
reasonably attributed to paracrine effects. Therefore beneficial
effects might be based on inhibition or reversing of negative
remodeling processes and the induction of neovascularization,
which then inhibits apoptosis of cardiomyocytes especially
within the border zone of the infarct. Thus the aim of
regenerating cardiac muscle in humans has jet not been
achieved. Despite identification of better candidate cell types
than BM-cells and establishment of definitive protocols for
stem cell propagation and differentiation, requirements to
overcome include characterization of biomarkers to monitor
stem cell fade after transplantation, validation of appropriate
imaging modalities, model systems demonstrating interactions
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between stem cells and local environment and cell
amplification procedures. Identification of molecules
guiding differentiation processes by secretome analyses
and bioinformatic approaches, will advance protein
based therapies to promote healing and inhibit patho-
logical remodeling of the heart after ischemia. On the
side of the individual patient genomic and microenvi-
ronment profiles should be employed using genomic
tools such as microarray analyses in a way to allow
calculation of adverse interactions based on an individ-
ual's metabolism, and prediction of therapeutic outcomes
[71]. None of the above obstacles will be overcome
without concomitant efforts to develop critically needed
enabling technologies.
Clearly, the field of stem cell therapy needs research
that would serve towards the purpose of individualized
treatments. The appearance of factors that influence
disease prognosis and clinical outcome vary not only with
donor stem cell function but also with genetic background of
the individual host. Ultimately, personalization of health
interventions, such as cell-based therapies, rests on a firm
understanding of the mechanisms of person to person
variations in treatment outcomes. Future studies to enhance
the identification of molecular differences will allow a
fundamental redefinition of diseases at the molecular and
cellular levels and enable identification of patients with
similar characteristics to estimate the outcome of treatment
strategies [30, 72]. The heterogeneity among patient factors
and the biology of different stem cell types merits the need
for personalized approach to stem cell therapy and other cell-
based treatments. Treatment employing stem cells holds
promising potential as a therapy to regenerate damaged
myocardium and might ultimately fulfill a large-scale of
unmet clinical need to improve the quality of life for millions
of people with ischemic heart disease.
The availability of pluripotent stem cells will however in
the near future influence medicine in many other ways than
tissue replacement. For instance, availability of cells that
can generate many differentiated cell types, may lead to the
development of protein or small molecule drugs that
influence differentiation not only from pluripotent stem
cells but also of multipotent stem cells residing in different
tissues and this not only in vitro but also in vivo, much like
the ability to culture hematopoietic stem cells led to the
development of erythropoietin and granulocyte colony
stimulating factor used in hematological disorders. The
ability to generate cells with pluripotent characteristics that
per definition differentiate in most cell types will also make
it possible to generate in vitro models of human disease
[73]. Moreover, availability of human cells differentiate to
e.g. cardiomyocyte is already of great interest for the
pharmaceutical industry for toxicity and metabolization
studies.
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